Recursion Pharmaceuticals (RXRX) Payables (2020 - 2025)
Historic Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $13.9 million.
- Recursion Pharmaceuticals' Payables rose 51659.29% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 51659.29%. This contributed to the annual value of $21.6 million for FY2024, which is 44113.67% up from last year.
- Recursion Pharmaceuticals' Payables amounted to $13.9 million in Q3 2025, which was up 51659.29% from $19.3 million recorded in Q2 2025.
- Recursion Pharmaceuticals' Payables' 5-year high stood at $25.1 million during Q1 2025, with a 5-year trough of $2.3 million in Q3 2024.
- Its 5-year average for Payables is $7.6 million, with a median of $4.9 million in 2023.
- Per our database at Business Quant, Recursion Pharmaceuticals' Payables tumbled by 5443.55% in 2024 and then skyrocketed by 51659.29% in 2025.
- Recursion Pharmaceuticals' Payables (Quarter) stood at $2.9 million in 2021, then skyrocketed by 60.98% to $4.7 million in 2022, then decreased by 14.71% to $4.0 million in 2023, then soared by 441.14% to $21.6 million in 2024, then plummeted by 35.52% to $13.9 million in 2025.
- Its Payables was $13.9 million in Q3 2025, compared to $19.3 million in Q2 2025 and $25.1 million in Q1 2025.